Skip to main content
Thanate Dajsakdipon on Muck Rack

Thanate Dajsakdipon

As seen in: BMC Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thanate

Contact Thanate, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand | BMC Cancer | Full Text

|
By Napa Parinyanitikul, Arunee Dechaphunkul, Patrapim Sunpaweravong, Charuwan Akewanlop, Thitiya Dejthevaporn, Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Archara Supavavej, Sunee Neesanun
| BMC Cancer Verified
Figure 1 illustrates the patient consort diagram, indicating that an initial 539 patients with HR + /HER2 − ABC receiving first-line therapy were collected from six tertiary care centers. Of these patients, 250 received first-line treatment with a combination of AI and CDK4/6i. Out of these 250 patients, PSM analysis revealed 183 matched patients for analysis, including 134 patients receiving AI combined with ribociclib and 49 patients treated with AI combined with palbociclib.
Open in Who Shared Issue with article?
See all 1 articles